Azacycles Introduces New Generation Of Nanobots For Design Of New Pharmaceuticals And Drugs

Souheast, Washington (I-Newswire) December 18, 2011 - So far several hundred types of nanocarriers for human medicine were proposed and several basic principles of the construction of nanocarriers and methods of placing the active ingredients in the nanocarrier. After almost 30 months of the intensive development Azacycles company introduces intelligent nanobots and demonstrates their sophisticated modification in Virus Trap technology, almost futuristic realization of antiviral agents of quite new conception. The nanobot patented technology is based on the hollow highly hydrophilic nano-spherical particles with polysaccharide fully covalent skeletons and implied Virus Trap technology is entirely independent on type of the virus and of course on surface epitopes of viruses. Simon Cihelnik, Ph.D. (CEO) commented this advancement:

"There are expected and expectable changes in the field of a human therapy in next two decades. Actual situation on the global market with nano-medicine’s targeted drugs, estimated requirements of the market in next years and exceptional parameters of the hollow highly hydrophilic nano-spherical particles with polysaccharide fully covalent skeletons have allowed to formulate the concept of development of a technological method for production of nanobotic modules for the targeted drug designing and manufacturing. We expect large area of application based on our Nanobot technology. Therefore constituted Nanobot Special Interest Group will be helpful. Presented Virus Trap technology is very rare approach from view of present antiviral agents or antiviral drugs’ design. We tast the technology like a logical step from making the idea, the new concept, from Azacycles’ nanobot technology, to utilizing of Azacycles’ Nanobot technology 1st generation outgoings in a supramolecular design of new pharmaceutical. Actually such approach is a literal fulfillment of the word development – from a concept, over an another technology result, into an expected therapeutic agent. Our nanobot technology in its first generation is able to provide excellent matrix of the antiviral, but only second generation, which is in state of its building, will allow to build antiviral nanobot in whole wide of our company’s aim."

He also confirmed the information that Azacycles seeks and carefully chooses another partners for cooperation in the Nanobot Special Interest Group (Nanobot SIG):

"We are looking for strong and interesting partners for Nanobot SIG. They should bring into the SIG entirely new application models of the nanobots with an extraordinary dose of excellence."

And what an impacts?

"Our nanobot technology brings an universal concept of a targeted drug module, i.e. a very high number of end third parties will be able “to colonise” the encapsulation of the targeted drug with their own biologically active ingredient and transfer it to the target form. The impact of such a solution, above all therapeutic, is enormous. Also it will simplify the development of targeted drugs because will provide to a third party a completed module of defined properties in the organism (half-time of disintegration, affinity to target tissue receptors, pharmacokinetics in the models) and thereby speed up the introduction of targeted drugs into practice." (http://www.azacycles.com/azacycles_research_development.html)

About Koho Koishu Biotechnology:
nanotechnology, biotechnology

Company Contact Information
Koho Koishu Biotechnology
Ed Northon
18217 121st Street
Souheast, Washington
98290
Phone : 9072431854